Compare COCP & SNAL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COCP | SNAL |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.6M | 21.2M |
| IPO Year | 2011 | 2022 |
| Metric | COCP | SNAL |
|---|---|---|
| Price | $1.11 | $2.27 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 51.5K | 20.0K |
| Earning Date | 11-13-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 54.65 | ★ 120.00 |
| EPS | ★ N/A | N/A |
| Revenue | $12,712,091.00 | ★ $81,225,622.00 |
| Revenue This Year | N/A | $22.50 |
| Revenue Next Year | N/A | $9.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.76 | $0.34 |
| 52 Week High | $2.03 | $5.92 |
| Indicator | COCP | SNAL |
|---|---|---|
| Relative Strength Index (RSI) | 39.79 | 28.95 |
| Support Level | $0.99 | $0.44 |
| Resistance Level | $1.12 | $2.70 |
| Average True Range (ATR) | 0.07 | 0.13 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 4.55 | 21.82 |
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI). The company has one reportable and operating segment dedicated to the research and development company's novel orally administered antiviral influenza candidate. The company has pipeline products for diseases like : Influenza, Norovirus, Coronavirus, Respiratory Viruses, and Hepatitis C.
Snail Inc is an independent developer and publisher of interactive digital entertainment for consumers around the world, with a portfolio of premium games designed for use on a variety of platforms, including consoles, PC's, and mobile devices. The geographic presence of the company is in the United States and the International market, where the majority of its revenue comes from the United States. The Company has one operating and reportable segment. The company operates in the USA, the UK and Other Countries.